Compare Build A Bear Workshop Inc (BBW) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Bristol-Myers Squibb Co — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Bristol-Myers Squibb Co trades at $57 (market cap $116.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 281.9× Build A Bear Workshop Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BBW | BMY | |
|---|---|---|
Market Cap | $412.61M | $116.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $62.37 |
52-Week Low | $29.84 | $42.60 |
Enterprise Value | $512.05M | $152.24B |
Dividend Yield | 2.8% | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.
BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
